Levoxyl — Class II drug recall D-0575-2025
Ongoing recall by Pfizer, reported 2025-08-20. Subpotent drug
| Recall number | D-0575-2025 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Pfizer, Manhattan, NY, United States |
| Recall initiated | 2025-07-29 |
| Classified | 2025-08-08 |
| Reported by FDA | 2025-08-20 |
| Reason classes | potency |
| NDC | 60793-0850, 60793-0850-01, 60793-0850-10, 60793-0851, 60793-0851-01, 60793-0851-10, 60793-0852, 60793-0852-01, 60793-0852-10, 60793-0853, 60793-0853-01, 60793-0853-10, 60793-0854, 60793-0854-01, 60793-0854-10, 60793-0855, 60793-0855-01, 60793-0855-10, 60793-0856, 60793-0856-01, 60793-0856-10, 60793-0857, 60793-0857-01, 60793-0857-10, 60793-0858 and 8 more |
| Lot numbers | 24C11 |
| Expiration dates | 2026-02-28 |
Product
Levoxyl (levothyroxine sodium tablets, USP), 50 mcg, 100-count bottle, Rx only, Distributed by: Pfizer Inc., New York, NY 10017, Made in Austria, NDC 60793-851-01.
Reason for recall
Subpotent drug
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0575-2025. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.